XFOR
X4 Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
FDA Approved
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XFOR
X4 Pharmaceuticals, Inc.
A late-stage clinical biopharmaceutical company that develops therapeutics of monoclonal antibodies for the targeted immunotherapy of serious infections
Biological Technology
08/02/2010
11/16/2017
NASDAQ Stock Exchange
143
12-31
Common stock
61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134
--
X 4 Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on August 2, 2010. The company is a late-stage clinical-stage biopharmaceutical company that discovers and develops new therapies for the treatment of rare diseases and diseases with limited treatment options, focusing on diseases caused by immune system dysfunction. The company's lead clinical candidate is mavorixafor, a small molecule selective antagonist of the chemokine receptor CXCR4, which is being developed as an oral, once-daily therapy. Because mavorixafor can increase the mobilization of mature, functional white blood cells into the bloodstream, the company believes that mavorixafor has the potential to provide therapeutic benefits in a variety of chronic neutropenia, including WHIM (warts, hypogammaglobulinemia, infection and myelochalasia) syndrome, a rare primary immunodeficiency.
Earnings Call
Q1/2025
Estimate EPS-3.75
Actual EPS0.04
Estimate Revenue7.03M
Actual Revenue28.81M
Regulatory Shifts and Patient Insights: Contradictions in Recent Clinical Trials Unveiled
May 09,2025 03:40
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
XFOR has released its 2025 Q3 earnings. EPS was reported at -0.69, versus the expected -0.84, beating expectations. The chart below visualizes how XFOR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XFOR has released its 2025 Q3 earnings report, with revenue of 1.76M, reflecting a YoY change of 215.18%, and net profit of -29.82M, showing a YoY change of 18.75%. The Sankey diagram below clearly presents XFOR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
